close

Enter

Log in using OpenID

Acute Heart Failure (AHF) Therapeutics Market

embed
Acute heart failure (AHF) is a progressive condition, in which, the heart muscle is unable to pump enough blood through the heart to meet body’ optimal blood and oxygen level.
Acute Heart Failure (AHF) Therapeutics
Market - Size, Share, Outlook, and
Opportunity Analysis 2018–2026
Acute heart failure (AHF) is a progressive condition, in which, the heart muscle is unable to pump
enough blood through the heart to meet body’ optimal blood and oxygen level. Congestive heart
failure is type of heart failure which requires timely medical attention. Moreover, distinguish
between acute and chronic heart failure is important from a clinical standpoint, on which further
medication depends. For this, N terminal proB-type natriuretic peptide levels are used for
distinguishing acute versus chronic left ventricular dysfunction. An elevated levels of natriuretic
peptide were present in patients with acute heart failure compared to those with chronic heart failure
patient.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1910
Heart failure symptoms vary widely from person to person, depending on types of heart failure
patient. The main symptoms of heart failure are caused due to fluid accumulation or congestion and
poor blood flow to the body. Symptoms caused by fluid accumulation or congestion includes
shortness of breath, weight gain, coughing, swollen ankles, legs or abdomen, while dizziness, rapid
heart rate, and fatigue are symptoms associated with reduced blood flow to parts of the body.
Acute Heart Failure (AHF) Therapeutics Market Drivers
The global acute heart failure therapeutics market is expected to witness significant growth due to
approval of new drugs. For instance, in July 2015, Novartis received U.S. Food and Drug
Administration (FDA) approval for their Entresto(TM) (sacubitril/valsartan) tablets on the treatment
of heart failure with reduced ejection fraction. Entresto is indicated to reduce the risk of
cardiovascular death and heart failure hospitalization.
Furthermore, robust pipeline of drugs over the forecast period (2018-2026), is another factor driving
growth of acute heart failure therapeutics market. For instance, in March 2017, Cardioxyl
Pharmaceuticals’ CXL-1427: a novel nitroxyl (HNO) donor (prodrug), which now operates under
the Bristol-Myers Squibb Company (after Cardioxyl Pharmaceuticals’ acquisition by Bristol-Myers
Squibb in December 2015); is present in Phase 2 clinical development phase. CXL-1427 is
indicated to use as an intravenous treatment for acute decompensated heart failure (ADHF).
Successful completion and further launch of Bristol-Myers Squibb’s innovative drug in future, will
help to boost the acute heart failure (AHF) therapeutics market growth during the forecast period.
Various lifestyle factors are responsible to increase risk heart attack and stroke, which includes
smoking, overweight, eating foods with high fat and cholesterol, and physical inactivity.
Furthermore, patients suffering with heart failure are at high risk to one or more conditions such as
coronary artery disease, myocardial infraction, high blood pressure or hypertension, abnormal heart
valves, dilated cardiomyopathy, hypertrophic cardiomyopathy, severe lung disease, obesity, and
sleep apnea, among others. For instance, according to the World Health Organization (WHO),
October 2017 data findings, in 2016, over 1.9 billion adults, were overweight, worldwide. Among
which over 650 million were obese. Moreover, according to the same source, raised BMI index,
owing to overweight and obesity are the major risk factors for cardiovascular disease, which was
the leading cause of death in 2012, worldwide.
Acute Heart Failure (AHF) Therapeutics Market Restraints
Acute heart failure is a common condition associated with considerable morbidity, mortality, and
cost. However, evidence-based data on treating heart failure in the acute setting are limited, and
current individual treatment options have variable efficacy. Furthermore, healthcare team often need
to customize patient care in acute heart failure treatment. For instance, dyspnea is the most common
symptom associated with AHF patients. However, this symptom is non-specific as other medical
conditions are commonly associated with dyspnea, including pneumonia, exacerbations of chronic
obstructive pulmonary disease, pulmonary embolism, acute coronary syndrome, and asthma. This is
another factor negatively affecting growth of the acute heart failure (AHF) therapeutics market.
Acute Heart Failure (AHF) Therapeutics Market – Regional Analysis
Geographically, the market is segmented into North America, Latin America, Europe, Middle East,
Asia Pacific, and Africa. North America is expected to hold dominant position in global acute heart
failure (AHF) therapeutics market, due to high prevalence of acute heart failure cases, in this region.
For instance, according to Centers for Disease Control and Prevention (CDC), June 2016, around
5.7 million adults in the U.S. suffered from heart failure, in 2016. Moreover, about half of the
people who develop heart failure die within 5 years of diagnosis.
Furthermore, growing prevalence of obesity have increased risk of developing acute heart failure
(AHF). According to CDC, May 2017 data findings, between 2013 and 2014, 37.9% of adults aged
20 years and over were obese, in the U.S. Therefore, high prevalence of risk factors and acute heart
failure (AHF) cases in these region are expected to drive growth of this market over the forecast
period.
Asia Pacific acute heart failure (AHF) therapeutics market is projected to witness significant
growth, due to increasing focus of healthcare organizations in creating awareness regarding
increasing risk factors of acute heart failure. For instance, in June 2016, Fortis Hospital, India
launched Fortis Heart Rhythm and Heart failure Centre in Bangalore, to increase awareness among
people regarding heart failure, stroke, and various other cardiovascular disease.
For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/acuteheart-failure-ahf-therapeutics-market-1910
Acute Heart Failure (AHF) Therapeutics Market – Competitive Landscape
Some of the key players in this market are Novartis AG, Cardiorentis AG, Bristol-Myers Squibb
Company, Amgen Inc., Bayer AG, Cytokinetics, Inc., Merck & Company, Inc., Ono Pharmaceutical
Co., Ltd., and Pfizer Inc., among others. Key players in the marker are engaged in development of
new drugs for acute heart failure (AHF). These players are incorporating collaboration strategies to
remain competitive in the market.
For instance, in October 2015, Cardiorentis AG announced plans to collaborate with Roche to
establish therapeutic efficacy and safety of Ularitide: Cardiorentis’ investigational drug for acute
heart failure (AHF). Under the terms of collaboration, Cardiorentis will incorporate Roche's
advanced in vitro diagnostic tests into its TRUE-AHF Phase III study to characterize the
pharmacological properties of Ularitide, evaluate its benefit-risk profile, and the appropriate clinical
application in patients.
Acute Heart Failure (AHF) Therapeutics Market Taxonomy
By Disorder Type
•Right-sided Heart Failure
•Left-sided Heart Failure
•Systolic Failure
•Diastolic Failure
•Congestive Heart Failure
By Drug Category
•Angiotensin-Converting Enzyme (ACE) Inhibitors
•Captopril (Capoten)
•Enalapril (Vasotec)
•Fosinopril (Monopril)
•Lisinopril (Prinivil, Zestril)
•Perindopril (Aceon)
•Quinapril (Accupril)
•Ramipril (Altace)
•Others
•Angiotensin II Receptor Blockers
•Candesartan (Atacand)
•Losartan (Cozaar)
•Valsartan (Diovan)
•Angiotensin-Receptor Neprilysin Inhibitors (ARNIs)
•Sacubitril/valsartan
•If Channel Blocker
•Ivabradine (Corlanor)
•Beta Blockers
•Bisoprolol (Zebeta)
•Metoprolol Succinate (Toprol XL)
•Carvedilol (Coreg)
•Others
•Aldosterone Antagonists
•Spironolactone (Aldactone)
•Eplerenone (Inspra)
•Diuretics
•Furosemide (Lasix)
•Bumetanide (Bumex)
•Torsemide (Demadex)
•Chlorothiazide (Diuril)
•Amiloride (Midamor Chlorthalidone (Hygroton)
•Hydrochlorothiazide or HCTZ (Esidrix, Hydrodiuril)
•Others
•Anticoagulants (Blood Thinners)
•Cholesterol Lowering Drugs (Statins)
•Digoxin
By Distribution Channel:
•Hospital Pharmacies
•Retail Pharmacies
•Online Pharmacies
By Region
•North America
•Latin America
•Europe
•Asia Pacific
•Middle East
•Africa
Request For Customization @ https://www.coherentmarketinsights.com/insight/requestcustomization/1910
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Author
sumit.p
sumit.p1   document Email
Document
Category
Health and Medicine
Views
12
File Size
105 KB
Tags
ahf
1/--pages
Report inappropriate content